Biotechnology News and Research

RSS

Australian university signs multi-million dollar anti-cancer research deal

Australia's University of Newcastle Research Associates (TUNRA) Ltd has signed a licensing agreement worth approximately $10 million with the biotechnology company Psiron Ltd to develop anti-cancer treatments.

5 Aug 2004

Promising new cancer drug, Nanotax

A Lawrence company that uses patented technology created at the University of Kansas to improve the effectiveness of drugs has won a $100,000 National Institutes of Health grant to support further testing of the company's promising new cancer drug, Nanotax.

5 Aug 2004

Renal research boost for the University of Birmingham

The Medical School at the University of Birmingham is amongst four UK winners of the prestigious Genzyme Renal Innovations Programme (GRIP).

2 Aug 2004

New approach to cancer vaccines may eradicate skin cancer tumors

Mayo Clinic and British researchers have developed a new approach to cancer vaccines that purposely kills healthy skin cells to target the immune system against tumors. The new approach has eradicated skin cancer tumors in mice.

2 Aug 2004

Philadelphia diet drug trial completed

Wyeth has announced that the jury in the case of Rhonda Istnick and Henry Clepper v. Wyeth, et al. rendered its decision, finding in favor of the Company in the case brought by Ms. Istnick, while awarding Mr. Clepper compensatory damages in the amount of $48,000.

29 Jul 2004

New method for detecting premature birth

Researchers at Oregon Health & Science University have discovered a method for detecting intra-amniotic infections in pregnant women using state-of-the-art methods.

29 Jul 2004

$1.6 million to develop gene therapy strategies for Duchenne muscular dystrophy, a fatal, childhood-onset disease

The Muscular Dystrophy Association has announced it has awarded $1.6 million to Asklepios, a biotechnology company closely allied with the University of North Carolina at Chapel Hill, to develop gene therapy strategies for Duchenne muscular dystrophy (DMD), a fatal, childhood-onset disease.

23 Jul 2004

Environmental Proteomics to design antibodies for the global market

The business fills a niche in the world market by manufacturing custom-made tools (antibodies) used in the study of proteins. Antibodies for use in typical laboratory subjects such as mammals are easily obtained, but it is very difficult to find these tools for use with other organisms, such as fish, plants, and algae. Recognizing the need for these products through his own research at Mount A over the last six years, Campbell appreciated the innovative applications of his findings.

21 Jul 2004

3M and MicroDose Technologies Inc. team up to bring advanced electronic dry powder inhaler to market

3M and MicroDose Technologies Inc., a privately held drug delivery company based in Monmouth Junction, N.J., announced today that the two companies have entered into an exclusive co-development and joint marketing agreement.

20 Jul 2004

Russian scientists incorporate HIV antigen into a tomato

Russian scientists are currently creating a pleasant and harmless vaccine, and edible one at that. So far, they managed to incorporate the protein gene – HIV antigen in tomatoes. The research is supported by International Science and Technology Center.

19 Jul 2004

CancerVax may increase the survival of patients with advanced stage non-small-cell lung cancer

CancerVax Corporation has announced that its wholly owned subsidiaries, Tarcanta, Inc., and Tarcanta, Ltd. (Ireland), have obtained the exclusive rights to complete the clinical development of three specific active immunotherapeutic (SAI) product candidates that target the epidermal growth factor receptor (EGFR) signaling pathway for the treatment of cancer.

19 Jul 2004

New drugs that can prevent scarring in the eye after glaucoma surgery

Highly innovative new drugs that can prevent scarring in the eye after glaucoma surgery have been discovered by a London-based team of scientists, who report today in the journal Nature Biotechnology.

19 Jul 2004

Market research 'World RNAi Markets: Current and Future Outlook'

Gene silencing by RNAi has now been identified as a crucial technology for target validation and therapeutics. By targeting and interfering with messenger RNA (mRNA), RNAi technology blocks the expression of the proteins implicated in disease progression.

19 Jul 2004

Strategic analysis of the breast cancer therapeutics pipeline

Strategic partnerships between the pharmaceuticals industry and the biotechnology sector are making breast cancer therapeutics one of the most dynamic segments in the overall oncology market.

15 Jul 2004

Genetic mutation is a major contributor to type 1 diabetes

A natural mutation of a gene that helps regulate the reactivity of the immune system is a major contributor to type 1 diabetes, Medical College of Georgia researchers have found.

12 Jul 2004

Natural products to be developed as anti-cancer therapeutics

The licence grants Zentaris exclusive worldwide rights for the development, manufacture and marketing of disorazoles, a novel class of natural products with strong anti-cancer potential discovered by GBF researchers.

8 Jul 2004

Gum disease vaccination aim of world-first research

Vaccinating people against gum disease will be the aim of world-first Melbourne research that today receives a $21.2 million boost from the Federal Government.

2 Jul 2004

Omega-3's - fatty acids, can be produced in bioengineered plants

Long-chain omega-3 polyunsaturated fatty acids (n-3 LC-PUFAs) have benefits regarding cardiovascular and inflammatory function, certain types of cancer, and maternal and infant health, according to recent peer-reviewed studies.

2 Jul 2004

Relatively difficult for the AIDS virus to develop resistance to the drug, tenofovir, or the DAPY (diarylpyrimidine) family of compounds

HIV is a moving target, unpredictably changing direction to elude anti-AIDS drugs, but researchers at Rutgers are clearly on the track of solutions to combat HIV drug resistance.

29 Jun 2004

Codex aims to keep up with gene technologies and potential health impact of genetically modified foods

The Codex Alimentarius Commission convened its 27th session today, one year ahead of schedule, amid calls for the Commission to implement recommendations made by Food and Agriculture Organization of the United Nations (FAO) and the World Health Organization (WHO) evaluation.

29 Jun 2004